Table 1.
Clinical characteristics of the study cohort at baseline (N = 92).
| Characteristics | No. of patients (%) |
|---|---|
| Age, median (range) | 57 (28–74) |
| Sex | |
| Male | 59 (64.1) |
| Female | 33 (35.9) |
| Histological type | |
| Adenocarcinoma | 78 (84.8) |
| Non-adenocarcinoma | 14 (15.2) |
| Smoking status | |
| Smokers | 41 (44.6) |
| Non-smokers | 51 (55.4) |
| ECOG PS | |
| 0–1 | 63 (68.5) |
| ≥ 2 | 29 (31.5) |
| CNS symptoms | |
| Yes | 49 (53.3) |
| No | 43 (46.7) |
| Brain tumor number | |
| 1–3 | 31 (33.7) |
| ≥ 4 | 61 (66.3) |
| Maximum brain tumor size (mm) | |
| Median (range) | 19.0 (5.0-47.4) |
| Thoracic stage a | |
| I–II | 12 (13.0) |
| IIIA | 29 (31.5) |
| IIIB | 40 (43.5) |
| IIIC | 11 (12.0) |
| Distant metastases | |
| Liver | 11 (12.0) |
| Bone | 45 (48.9) |
| Adrenal gland | 19 (20.7) |
| Gene mutation | |
| EGFR mutation | 44 (47.8) |
| ALK rearrangement | 3 (3.3) |
| EGFR/ALK wild-type | 45(48.9) |
| Lung-molGPA b | |
| 0–1 | 8 (8.7) |
| 1.5–2 | 23 (25.0) |
| 2.5–3 | 44 (47.8) |
| 3.5–4.5 | 17 (18.5) |
| First-line treatment | |
| Chemotherapy | 35 (38.0) |
| Immunotherapy | 10 (10.9) |
| Tyrosine kinase inhibitors (TKIs) | 47 (51.1) |
| With tumor tissues | 58 (63.0) |
| Primary lung tumors | 38 (41.3) |
| Lymph nodes | 20 (21.7) |
| Without tumor tissues | 34 (37.0) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; CNS, central nervous system; TKIs, tyrosine kinase inhibitors
aThoracic stage was calculated according to 8th American Joint Committee on Cancer (AJCC) staging system
bAn update of the diagnosis-specific Graded Prognostic Assessment (DS-GPA) using molecular markers